

**FIRST ENGROSSMENT  
with House Amendments**

Sixtieth  
Legislative Assembly  
of North Dakota

**ENGROSSED SENATE BILL NO. 2134**

Introduced by

Senator J. Lee

(At the request of the State Board of Pharmacy)

1 A BILL for an Act to create and enact chapter 19-03.5 of the North Dakota Century Code,  
2 relating to a prescription drug monitoring program for controlled substances; to repeal section  
3 50-06-27 of the North Dakota Century Code, relating to a prescription drug monitoring program;  
4 to provide a penalty; and to declare an emergency.

5 **BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:**

6 **SECTION 1.** Chapter 19-03.5 of the North Dakota Century Code is created and  
7 enacted as follows:

8 **19-03.5-01. Definitions.**

- 9 1. "Board" means the state board of pharmacy.
- 10 2. "Central repository" means a place where electronic data related to the prescribing  
11 and dispensing of controlled substances is collected.
- 12 3. "Controlled substance" means a drug, substance, or immediate precursor defined  
13 in section 19-03.1-01 and nonscheduled substances containing tramadol or  
14 carisoprodol.
- 15 4. "De-identified information" means health information that is not individually  
16 identifiable information because an expert has made that determination under  
17 title 45, Code of Federal Regulations, section 164.514 or direct identifiers and  
18 specified demographic information have been removed in accordance with the  
19 requirements of that section.
- 20 5. "Dispense" means to deliver a controlled substance to an ultimate user by or  
21 pursuant to the lawful order of a practitioner, including the prescribing,  
22 administering, packaging, labeling, or compounding necessary to prepare the  
23 substance for delivery.

- 1           6. "Dispenser" means an individual who delivers a controlled substance to the  
2           ultimate user but does not include a licensed hospital pharmacy that provides a  
3           controlled substance for the purpose of inpatient hospital care or a licensed health  
4           care practitioner or other authorized individual in those instances when the  
5           practitioner administers a controlled substance to a patient.
- 6           7. "Individually identifiable health information" has the meaning set forth in title 45,  
7           Code of Federal Regulations, section 160.103.
- 8           8. "Patient" means an individual or the owner of an animal who is the ultimate user of  
9           a controlled substance for whom a prescription is issued or for whom a controlled  
10          substance is dispensed.
- 11          9. "Prescriber" means an individual licensed, registered, or otherwise authorized by  
12          the jurisdiction in which the individual is practicing to prescribe drugs in the course  
13          of professional practice.
- 14          10. "Program" means the prescription drug monitoring program implemented under  
15          this chapter.

16          **19-03.5-02. Requirements for prescription drug monitoring program.**

- 17          1. The board shall establish and maintain a program for the monitoring of prescribing  
18          and dispensing of all controlled substances.
- 19          2. Each dispenser shall submit to the board by electronic means information  
20          regarding each prescription dispensed for a controlled substance. The information  
21          submitted for each prescription must include all of the data elements in the  
22          American society for automation in pharmacy rules-based standard  
23          implementation guide for prescription monitoring programs issued August 31,  
24          2005, version 003, release 000.
- 25          3. Each dispenser shall submit the information in accordance with transmission  
26          methods and frequency established by the board.
- 27          4. The board may issue an extension of time to a dispenser that is unable to submit  
28          prescription information by electronic means.

29          **19-03.5-03. Access to prescription information.**

- 30          1. Information submitted to the central repository is confidential and may not be  
31          disclosed except as provided in this section.

- 1           2. The board shall maintain procedures to ensure that the privacy, confidentiality, and  
2           security of patient information collected, recorded, transmitted, and maintained is  
3           not disclosed except as provided in this section.
- 4           3. Unless disclosure is prohibited by law, the board may provide data in the central  
5           repository to:
- 6           a. A prescriber for the purpose of providing medical care to a patient, a  
7           dispenser for the purpose of filling a prescription or providing pharmaceutical  
8           care for a patient, a prescriber or dispenser inquiring about the prescriber's or  
9           dispenser's own prescribing activity, or a prescriber or dispenser in order to  
10           further the purposes of the program;
- 11           b. An individual who requests the prescription information of the individual or the  
12           individual's minor child;
- 13           c. State boards and regulatory agencies that are responsible for the licensing of  
14           individuals authorized to prescribe or dispense controlled substances if the  
15           board or regulatory agency is seeking information from the central repository  
16           that is relevant to an investigation of an individual who holds a license issued  
17           by that board or regulatory agency;
- 18           d. Local, state, and federal law enforcement or prosecutorial officials engaged in  
19           the enforcement of laws relating to controlled substances who seek  
20           information for the purpose of an investigation or prosecution of the  
21           drug-related activity or probation compliance of an individual;
- 22           e. The department of human services for purposes regarding the utilization of  
23           controlled substances by a medicaid recipient;
- 24           f. Workforce safety and insurance for purposes regarding the utilization of  
25           controlled substances by a claimant;
- 26           g. Judicial authorities under grand jury subpoena or court order or equivalent  
27           judicial process for investigation of criminal violations of controlled substances  
28           laws;
- 29           h. Public or private entities for statistical, research, or educational purposes after  
30           the information is de-identified with respect to any prescriber, dispenser, or  
31           patient who received a prescription for a controlled substance; or

- 1           i. A peer review committee which means any committee of a health care  
2           organization, composed of health care providers, employees, administrators,  
3           consultants, agents, or members of the health care organization's governing  
4           body, which conducts professional peer review as defined in chapter 23-34.
- 5           4. The board shall maintain a record of each person who requests information from  
6           the central repository. The board may use the records to document and report  
7           statistics and outcomes. The board may provide records of the requests for  
8           information to:
- 9           a. A board or regulatory agency responsible for the licensing of individuals  
10           authorized to prescribe or dispense controlled substances that is engaged in  
11           an investigation of the individual who submitted the request for information  
12           from the central repository; and
- 13           b. Local, state, and federal law enforcement or prosecutorial officials engaged in  
14           the enforcement of laws relating to controlled substances for the purpose of  
15           an active investigation of an individual who requested information from the  
16           central repository.

17           **19-03.5-04. Authority to contract.** The board is authorized to contract with another  
18 agency of this state or with a private vendor to facilitate the effective operation of the  
19 prescription drug monitoring program. Any contractor is bound to comply with the provisions  
20 regarding confidentiality of prescription drug information in this chapter and is subject to  
21 termination or sanction or both for unlawful acts.

22           **19-03.5-05. Immunity.** Nothing in this chapter requires a prescriber or dispenser to  
23 obtain information about a patient from the central repository prior to prescribing or dispensing  
24 a controlled substance. A prescriber, dispenser, or other health care practitioner may not be  
25 held liable in damages to any person in any civil action on the basis that the prescriber,  
26 dispenser, or other health care practitioner did or did not seek to obtain information from the  
27 central repository. Unless there is shown a lack of good faith, the board, any other state  
28 agency, a prescriber, dispenser, or any other individual in proper possession of information  
29 provided under this chapter may not be subject to any civil liability by reason of:

- 30           1. The furnishing of information under the conditions provided in this chapter;  
31           2. The receipt and use of, or reliance on, such information;

- 1           3.   The fact that any such information was not furnished; or  
2           4.   The fact that such information was factually incorrect or was released by the board  
3                 to the wrong person or entity.

4           **19-03.5-06. Data review and referral - Corrections.**

- 5           1.   a.   The board shall review the information received by the central repository to  
6                 determine if there is reason to believe:  
7                 (1)   A prescriber or dispenser may have engaged in an activity that may be  
8                 a basis for disciplinary action by the board or regulatory agency  
9                 responsible for the licensing of the prescriber or dispenser; or  
10                (2)   A patient may have misused, abused, or diverted a controlled  
11                 substance.  
12           b.   If the board determines that there is reason to believe that any of the acts  
13                 described in subdivision a may have occurred, the board may notify the  
14                 appropriate law enforcement agency or the board or regulatory agency  
15                 responsible for the licensing of the prescriber or dispenser. The advisory  
16                 council described in section 19-03.5-07 shall recommend guidelines to the  
17                 board for reviewing data and making determinations with respect to the  
18                 referral of patients, prescribers, or dispensers to law enforcement or  
19                 appropriate regulatory authorities.  
20           2.   A patient, dispenser, or prescriber may request that erroneous information  
21                 contained in the central repository be corrected or deleted. The board shall review  
22                 the request to determine if the information is erroneous with respect to the patient,  
23                 prescriber, or dispenser. The board shall correct any erroneous information the  
24                 board discovers due to the request for review by a patient, prescriber, or  
25                 dispenser.  
26           3.   The board shall adopt a procedure to allow information contained in the central  
27                 repository to be shared with officials in other states acting for the purpose of  
28                 controlled substance monitoring and for requesting and receiving similar controlled  
29                 substance monitoring information from other states.

30           **19-03.5-07. Advisory council.**

- 1           1. An advisory council is established to advise and make recommendations to the  
2           board regarding how to best use the program to improve patient care and foster  
3           the goal of reducing misuse, abuse, and diversion of controlled substances; to  
4           encourage cooperation and coordination among state, local, and federal agencies  
5           and other states to reduce the misuse, abuse, and diversion of controlled  
6           substances; and to provide advice and recommendations to the board regarding  
7           any other matters as requested by the board. The advisory council may have  
8           access to central repository information to fulfill its duties.
- 9           2. The advisory council must consist of:
  - 10           a. One dispenser selected by the board;
  - 11           b. One physician selected by the North Dakota medical association;
  - 12           c. One prescriber selected by the board of nursing;
  - 13           d. A designee of the attorney general;
  - 14           e. A designee of the department of human services;
  - 15           f. One prescriber selected by the board of medical examiners;
  - 16           g. One prescriber selected by the North Dakota nurses association; and
  - 17           h. Any other prescriber or dispenser determined by the board to be necessary to  
18           meet a mandate of, or avoid a delay in implementing, an appropriations  
19           measure. The number of additional members selected by the board must be  
20           limited to the number necessary to meet the mandate or avoid the delay of an  
21           appropriation.
- 22           3. The advisory council shall make recommendations to the board regarding:
  - 23           a. Safeguards for the release of information to individuals who have access to  
24           the information contained in the central repository;
  - 25           b. The confidentiality of program information and the integrity of the patient's  
26           relationship with the patient's health care provider;
  - 27           c. Advancing the purposes of the program, including enhancement of the quality  
28           of health care delivery in this state; and
  - 29           d. The continued benefits of maintaining the program in relationship to the cost  
30           and other burdens to the state.

1           4.   The board may provide reimbursement of expenses and per diem to members of  
2                   the advisory council within the limits provided in state law.

3           **19-03.5-08. Extraterritorial application.** The board may provide data in the central  
4 repository to a practitioner or controlled substances monitoring system in another state, if the  
5 disclosure to a practitioner or the prescription drug monitoring program located in this state is  
6 authorized by this chapter.

7           **19-03.5-09. Authority to adopt rules.** The board may adopt rules that set forth the  
8 procedures and methods for implementing this chapter.

9           **19-03.5-10. Reporting unlawful acts and penalties.**

10          1.   The board may report to a dispenser's licensing board any dispenser who  
11                   knowingly fails to submit prescription drug monitoring information to the board as  
12                   required by this chapter or who knowingly submits incorrect prescription  
13                   information to the board.

14          2.   A person, including a vendor, who uses or discloses prescription drug monitoring  
15                   information in violation of this chapter is subject to the penalty provided in section  
16                   12.1-13-01.

17          **SECTION 2. REPEAL.** Section 50-06-27 of the North Dakota Century Code is  
18 repealed.

19          **SECTION 3. EMERGENCY.** This Act is declared to be an emergency measure.